期刊文献+

不同专业影像医生采用PI-RADS评分诊断有临床意义前列腺癌的差异性研究 被引量:9

Comparison of the diagnostic accuracy of clinically significant prostate cancer based on the PI-RADS:an interobserver study
原文传递
导出
摘要 目的比较全科影像医生和泌尿影像医生基于前列腺影像报告和数据系统(PI—RADS)诊断有临床意义前列腺癌的差异。方法回顾性分析2015年8月至2018年2月北京和睦家医院45例行前列腺多参数核磁(mpMRI)检查以及核磁靶向认知融合前列腺穿刺患者的临床资料。年龄(60.0±8.0岁),前列腺特异性抗原(PSA)中位值7.2ng/ml(1.2~95.8ng/ml),前列腺体积中位值45.0ml(18.3~127.0ml)。由北京和睦家医院全科影像医生根据PI-RADS 2.0进行诊断和PI—RADS评分。之后由首都医科大学附属北京安贞医院1名高年资主治泌尿影像医生单盲重新阅片,同样根据PI—RADS 2.0进行评分。PI-RADS≥3分的患者怀疑有临床意义前列腺癌。分析全科影像医生和泌尿影像医生对前列腺癌,尤其是有临床意义前列腺癌诊断的准确性及阳性预测价值(PPV)。结果全科影像医生诊断PI—RADS评分中位值3.0分,其中1、2、3、4、5分者分别为0、8、19、14、4例。泌尿影像医生诊断PI-RADS评分中位值2,8分,其中1、2、3、4、5分者分别为4、24、5、1、11例,二者的评分分布差异无统计学意义(P=0.064)。45例穿刺病理共检出前列腺癌14例,其中有临床意义前列腺癌9例。全科影像医生诊断PI-RADS≥3分者37例(82.2%),而泌尿影像医生诊断PI—RADS≥3分者17例(37.8%)。二者诊断的一致率仅17.8%(8/45)。全科影像医生和泌尿影像医生诊断PI—RADS≥3分对前列腺癌的PPV分别为35.1%(13/37)和76.5%(13/17),对有临床意义前列腺癌的PPV分别为21.6%(8/37)和52.9%(9/17)。结论泌尿影像医生采用PI—RADS评分对有临床意义前列腺癌的预测价值高于全科影像医生。在有泌尿影像诊断经验的中心可以尝试只对高PI-RADS评分患者进行穿刺活检,以减少不必要穿刺。 Objective To compare the diagnostic accuracy of clinically significant prostate cancer by general radiologist and uroradiology specialist based on the Prostate Imaging Reporting and Data System (PI-RADS).Methods A total of 45 men from Beijing United Family Hospital and Clinics undergoing prostate mpMRI examination and subsequent MRI-targeted biopsy were included in the study.The age of patients was (60.0±8.0)years ,the median PSA level was 7.2ng/ml (1.2-95.8ng/ml)and the median prostate volume was 45.0ml (18.3-127.0ml).The general radiologists from Beijing United Family Hospital and Clinics made the diagnosis according to PI-RADS 2.0.One uroradiology specialist from Beijing Anzhen hospital reviewed all the mpMRIs retrospectively and marked new PI-RADS score based on PI-RADS 2.0.The PI-RADS ≥3lesion was recognized as suspicious of clinically significant prostate cancer.The distribution of PI-RADS score from different doctors and the diagnostic accuracy of clinically significant prostate cancer was compared.Results All the 45 patients underwent MRI-targeted cognitive biopsy and 14 cases of prostate cancer were detected,including 9 cases of clinically significant prostate cancer.There was no significant difference in the distribution of PI-RADS by general radiologist and uroradiology specialist(P = 0.064).82.8%(37/45)and 37.8%(17/45)patients were diagnosed with PI-RADS≥3by general radiologist and uroradiology specialist respectively.The interobserver agreement was only 17.8%(8/45). The positive predictive value of PI-RADS≥3was 35.1%(13/37)and 76.5%(13/17)for prostate cancer by general radiologist and uroradiology specialist respectively,and for clinically significant prostate cancer, the positive predictive value of PI-RADS ≥3was 21.6%(8/37)and 52.9%(9/17)respectively. Conclusions Uroradiology specialist achieved significantly superior in predietive value of PI-RADS for clinically significant prostate cancer compared with general radiologist.In the experienced centers,MRI-targeted biopsy could be performed only on high PI-RADS score lesions ,thus to reduce unnecessary biopsies and to avoid over diagnosis and over treatment of prostate cancer.
作者 罗南 张凯 李鸿波 范占明 朱刚 Luo Nan;Zhang Kai;Li Hongbo;Fan Zhanming;Zhu Gang(Department of Radiology,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2018年第12期922-925,共4页 Chinese Journal of Urology
关键词 前列腺肿瘤 前列腺影像报告和数据系统 核磁共振 靶向穿刺 影像科医生 Prostatic neoplasms Prostate imaging reporting and data system (PI-RADS) Magnetic resonance imaging Targeted biopsy Radiologist
  • 相关文献

参考文献4

二级参考文献29

  • 1Hong-WenGao,Yu-LinLi,ShanWu,Yi-ShuWang,Hai-FengZhang,Yu-ZhuoPan,LingZhang,HirooTateno,IkuroSato,MasaakiKuwahara,Xue-JianZhao.Mass screening of prostate cancer in a Chinese population:the relationship between pathological features of prostate cancer and serum prostate specific antigen[J].Asian Journal of Andrology,2005,7(2):159-163. 被引量:20
  • 2Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [ J]. CA Cancer J Clin, 2015, 65: 87-108. DOI: 10. 3322/ caac. 21262.
  • 3HalpernEJ, StrupSE. Using gray-scale and color and power Doppler sonography to detect prostatic cancer[J]. AJR Am J Roentgenol, 2000, 174:623-627. DOI: 10.2214/ajr.174.3.1740623.
  • 4El-Shater BosailyA, ParkerC, BrownLC, et al. PROMIS - Prostate MR imaging study: a paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer[J]. Contemp Clin Trials, 2015, 42:26-40. DOI: 10.1016/j.cct.2015.02.008.
  • 5TairaAV, MerrickGS, GalbreathRW, et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting[J]. Prostate Cancer Prostatic Dis, 2010, 13:71-77. DOI: 10.1038/pcan.2009.42.
  • 6VilanovaJC, Barcelo-VidalC, CometJ, et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer[J]. AJR Am J Roentgenol, 2011, 196:W715-722. DOI: 10.2214/AJR.10.5700.
  • 7DelongchampsNB, RouanneM, FlamT, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging[J]. BJU Int, 2011, 107:1411-1418. DOI: 10.1111/j.1464-410X.2010.09808.x.
  • 8FranielT, StephanC, ErbersdoblerA, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning[J]. Radiology, 2011, 259(1):162-172. DOI: 10.1148/radiol.10101251.
  • 9PintoPA, ChungPH, RastinehadAR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging[J]. J Urol, 2011, 186:1281-1285.DOI: 10.1016/j.juro.2011.05.078.
  • 10TamselS, KilliR, HekimgilM, et al. Transrectal ultrasound in detecting prostate cancer compared with serum total prostate-specific antigen levels[J]. J Med Imaging Radiat Oncol, 2008, 52:24-28. DOI: 10.1111/j.1440-1673.2007.01906.x.

共引文献57

同被引文献122

引证文献9

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部